| AN OPEN LABEL, SINGLE ARM, MULTICENTER,SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT |
Completed |
Atezolizumab (MPDL3280A; RO5541267) |
3 |
MO29983 |
KFSH & RC-R |
| An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency |
Completed |
Sebelipase alfa (SBC-102) |
2 |
LAL-CL03 |
KFSH & RC-R |
| "An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure " |
Completed |
Dapagliflozin |
3 |
D169CC00001 |
KKUH |
| An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Ongoing |
Hydroxychloroquine sulphate |
3 |
version 8 |
QCH |
| "ALL SCTped 2012 FORUM Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia" |
Ongoing |
BUSULFAN |
3 |
CT17/016/R |
NGHA-R |
| Adjunct Low Dose Ketamine Infusion Versus Standard of Care in Mechanically Ventilated Critically Ill Patients at a Tertiary Saudi Hospital (ATTAINMENT Trial): Randomized, Prospective, Pilot Trial |
Ongoing |
Ketamine |
3 |
2191187 |
KFSH & RC-R |
| A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. |
Ongoing |
RO7034067 |
2 |
BP39056 |
KFSH&RC-R |
| A Trial of Favipiravir in Adults with Mild Coronavirus Disease Covid-19 |
Ongoing |
Favipiravir |
3 |
RC20/220/R |
NGHA-R |
| A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19 |
Terminated |
Favipiravir |
3 |
RC20/174/R |
NGHA-R |
| A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. |
Rejected |
Everolimus + Exemestane VS. Everolimus VS. Capecitabine |
2 |
CRAD001Y2201 |
KFSH & RC-R |
